On December 18, 2020 Scopus BioPharma Inc. (Nasdaq: SCPS) reported the closing of its initial public offering (Press release, Scopus BioPharma, DEC 18, 2020, View Source,over%2Dallotment%20option%20in%20full. [SID1234573074]). The underwriters for the initial public offering exercised their over-allotment option in full.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The company offered 575,000 shares of common stock, including shares issued for the over-allotment option, at a public offering price of $5.50 per share.
The company’s common stock trades on the Nasdaq Global Market under the ticker symbol "SCPS".
The Benchmark Company, LLC acted as Sole Bookrunning Manager and Joseph Gunnar & Co., LLC acted as Co-Manager for the offering.
Greenberg Traurig, LLP acted as counsel to the company. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. acted as counsel to the underwriters.
Scopus BioPharma intends to use the proceeds of the offering principally to further development of the company’s lead drug candidate, a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers.
An offering statement relating to the shares of common stock was filed with the U.S. Securities and Exchange Commission ("SEC") and became qualified on December 14, 2020. An offering circular relating to the offering was filed with the SEC and is available on the SEC’s website at View Source Copies of the offering circular may be obtained by contacting: The Benchmark Company, LLC, Attention: Prospectus Department, 150 E. 58th Street, 17th Floor, New York, NY 10155, by calling (212) 312-6700 or by e-mail at [email protected]; or Joseph Gunnar & Co., LLC, Attention: Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, by calling (212) 440-9600 or by email at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.